ANXA1 and nasopharyngeal carcinoma: In a mouse model for multiple myeloma, AnxA1 depletion improved bortezomib treatment [101], but in nasopharyngeal carcinoma xenografts, loss of AnxA1 enhanced radiotherapy resistance [102] (Table 1g).